Pay in 4 interest-free payments of $6.31 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Brief Communication: Glucagon-like peptide-1 receptor agonists for major cardiovascular and kidney outcomes in type 1 diabetes
Feeling bloated on tirzepatide happens because it affects digestion, not because youre gaining weight or keeping water
In SURMOUNT-5, patients on tirzepatide lost an average of 20.2% of their body weight over 72 weeks (about 50 pounds for a 250-pound person), compared to 13.7% (about 33 pounds) with semaglutide
Tirzepatide (LY3298176) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly for the treatment of type 2 diabetes and obesity
Comparing Zepbound with Other GLP-1s The rules for Zepbound generally apply to other branded medications in the same class
